Search

Copyright of Evaluation & Analysis of Drug-Use in Hospitals of China is the property of Evaluation & Analysis of Drug-Use in Hospitals of China Editorial Board and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To investigate the clinical characteristics, treatment and prognosis of primary cervical malignant melanoma. Methods: The clinical data and follow-up data of 13 patients with primary cervical malignant melanoma diagnosed by pathology in Affiliated Cancer Hospital of Zhengzhou University were collected from January 2013 to December 2019. Analysis the clinical characteristics, treatment and prognosis. Results: The 13 patients were 30-64 years old, with an average age of (51.1±10.8) years old. According to FIGO 2018 staging system, there were 4 stage Ⅰ patients, 3 stage Ⅱ patients, 1 stage Ⅲ patient, and 5 stage Ⅳ patients. Six patients with stage ⅠA-ⅡA were treated with surgery, of which 2 patients received observation only, 3 patients received chemotherapy after surgery, and one patient received chemotherapy+immunotherapy. Two patients with stage ⅡB to Ⅲ and two patients with stage Ⅳ received radiotherapy + chemotherapy. The remaining 3 patients with stage Ⅳ received a combination of chemotherapy, local radiotherapy, immunotherapy or targeted therapy. The median follow-up time was 12 months (7-84 months), 9 patients died, distant metastasis occurred in 3 cases, and the median overall survival was 38 months. Conclusions: Primary cervical malignant melanoma is a relatively rare but highly malignant tumor with poor prognosis and susceptibility to distant metastasis. Surgical resection is the main treatment modality for early-stage patients, and a combination of immunotherapy and targeted therapy may be a new option for metastatic and unresectable patients. [ABSTRACT FROM AUTHOR]

Copyright of Evaluation & Analysis of Drug-Use in Hospitals of China is the property of Evaluation & Analysis of Drug-Use in Hospitals of China Editorial Board and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)